In this direction, the evaluation of sarcopenia represents the most promising tool, whereas laboratory biomarkers (such as p16INK4a, myostatin and Insulin-like Growth Factor 1) are still at a very experimental stage [76]. The gene discussed is IGF1; the disease is sarcopenia.